Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose in patients with moderate to severe renal impairment.

No dose adjustment is required based on age
No dose adjustment is required based on age

Clinical study

In an open-label study, the pharmacokinetics of Januvia (sitagliptin) were assessed in patients with differing degrees of renal impairment and those with end-stage renal disease on haemodialysis (ESRD). Patients were administered a reduced single dose of 50mg sitagliptin.

A clinically significant increase in plasma concentration of sitagliptin was not observed in patients with mild renal impairment in comparison with normal healthy patients. In contrast, an approximate 2-fold increase in plasma AUC of sitagliptin was seen in patients with moderate renal impairment and an approximate 4-fold increase was observed in patients with severe renal impairment and patients with ESRD on haemodialysis.

Dosage recommendations

No dose adjustment is required in patients with mild renal insufficiency (CrCl ≥50ml/min). For patients with moderate renal impairment (CrCl 30 to 50ml/min), the dose of Januvia is 50mg once daily. In patients with severe renal impairment (CrCl <30ml/min) or end-stage renal disease requiring dialysis, the dose of Januvia is 25mg once daily.

Renal function should be assessed before starting and measured periodically thereafter.

Recommendations do not apply to Janumet

The combination product Janumet (sitagliptin + metformin) is still contraindicated in patients with moderate to severe renal impairment owing to the metformin component.

View Januvia drug record

View Janumet drug record

Further information: Merck Sharp & Dohme Ltd

Updated 27 April 2012

New strengths of Januvia available

Januvia is now available as 25mg and 50mg tablets to facilitate dosing in moderate to severe renal impairment.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)